Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 28th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.
Representative Lisa C. McClain also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
- Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/30/2026.
- Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
- Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
- Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
- Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
- Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
- Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.
ImmunityBio Stock Up 1.1%
Shares of ImmunityBio stock opened at $9.91 on Thursday. The company has a market cap of $10.50 billion, a P/E ratio of -10.22 and a beta of 0.02. The firm’s 50 day moving average price is $8.48 and its 200-day moving average price is $7.94. ImmunityBio, Inc. has a 52-week low of $1.95 and a 52-week high of $12.43.
Insider Buying and Selling at ImmunityBio
In other news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the sale, the director owned 100,309 shares in the company, valued at $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares of the company’s stock, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by corporate insiders.
Institutional Trading of ImmunityBio
Several large investors have recently added to or reduced their stakes in the company. Markowski Investments purchased a new stake in ImmunityBio in the second quarter valued at approximately $29,000. GAMMA Investing LLC increased its holdings in ImmunityBio by 262.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock worth $36,000 after buying an additional 2,756 shares during the period. Geneos Wealth Management Inc. raised its position in ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after buying an additional 4,907 shares during the last quarter. Western Wealth Management LLC purchased a new position in ImmunityBio during the 1st quarter worth approximately $44,000. Finally, Hollencrest Capital Management acquired a new stake in ImmunityBio during the 2nd quarter valued at approximately $44,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $14.00 target price on shares of ImmunityBio in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target on shares of ImmunityBio in a research note on Wednesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.
Read Our Latest Report on ImmunityBio
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
ImmunityBio Company Profile
ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.
Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.
Featured Stories
- Five stocks we like better than ImmunityBio
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
